ALS drug sets the stage for fresh FDA de­bate; Im­plo­sions every­where you look; Big names turn up at biotechs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

In­ter­est­ed in men­tal health? My col­league Nicole De­Feud­is is host­ing a vir­tu­al pan­el next week on how a new brand of biotech is out to use mod­i­fied psy­che­delics to rewire the brain in search of new and bet­ter ther­a­pies. You can at­tend at no cost and it promis­es to be a dy­nam­ic con­ver­sa­tion. Check it out here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.